AAT Wound Care is A leading provider in groundbreaking wound repair and tissue regeneration solutions.
Harnessing the power of amnion for the treatment of chronic wounds
A Powerful Regenerative Wound Matrix to Support Acute and Chronic Wound Closure Dermacyte® products are derived from human postpartum amniotic tissues that have been processed to retain native extracellular matrix cytokines, growth factors, and collagen to support tissue remolding, improving patient outcomes and treatment comfort.
Epithelium
Layers of Human Amniotic Membrane
Basement Membrane Compact Layer
Fibroblast Layer
Spongy Layer
Clinical Applications Dermacyte® products are versatile coverings and void fillers that may be applied to various hard-to-heal wounds, including: • Diabetic foot ulcers • Venous stasis ulcers • Burns • Decubitus / Pressure Ulcers • Surgical incisions • Other dermal defects and wounds
Easy to Use Ready for Application
• Dehydrated for easy application with no refrigeration • No preparation time required for thawing or soaking— reducing operative time Easy to Handle • Conforms to wound bed and naturally hydrates in place • Superior handling and optimal bioabsorption properties Improved Patient Experience Use as protective wound barrier to provide an antimicrobial, growth factor rich healing environment Promotes native tissue repair by minimizing fibrosis, reducing inflammation, and maximizing patient comfort Simple Wound Monitoring Routine dressing changes, wound cleansing, and Dermacyte® reapplication allows for easy assessment of wound closure.
Dermacyte®–A Unique Bioactive Wound Covering
Scaffolds: The special structure and biological viability of amniotic membrane is ideal in tissue engineering. The extracellular matrix components of the basement membrane creates a natural scaffold for cell attachment. 1
Signals: Amniotic tissue is rich in cytokines, growth factors, and stem cells that play a role in improved healing and regeneration and decreased immunogenicity. 2
Dermacyte® Matrix
SIZE 2 x 2 cm2 2 x 4 cm2 4 x 4 cm2 4 x 6 cm2 4 x 8 cm2
PRODUCT CODE AM-D10022 AM-D10024 AM-D10044 AM-D10046 AM-D10048
Cells: Sufficient cues to allow for cell attachment and proliferation are properties of dehydrated amnion. Soluble factors secreted by human dermal fibroblasts cultured on amnion enhanced both endothelial cell and keratino- cyte survival and endothelial cell migration in a wound closure assay. 3
Actual sizes:
2cm x 2cm
2cm x 4cm
4cm x 4cm
Committed to Patient Safety • All tissues are recovered and processed by a
U.S. FDA registered and AATB accredited tissue bank • A Licensed Medical Director confirms product eligibility through donor screening and testing records, and final culturing and sterility testing is confirmed prior to lot release
For information related to Dermacyte insurance benefit verifications, assistance or claims appeal assistance, please contact our
Reimbursement Support Line. Phone: (919) 921-8105 Ext 119 Fax: (919) 267-3753 Email: info@merakris.com
Merakris Therapeutics Inc 800 Park Offices Drive, Suite 3322 Research Triangle Park, NC 27709 919.921.8105 www.merakris.com FDA Establishment Identifier (FEI): 3013695841
References: 1. Niknejad H et al. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater. 2008 Apr 29;15:88-99. 2. Haugh A et al. Amnion membrane in diabetic foot wounds: a meta-analysis. Plastic and Reconstr Surg Glob Open. 2017 Apr; 5:e1302. 3. Guo et al. Modulation of cell attachment, proliferation, and angiogenesis by decellularized, dehydrated human amniotic membrane in in vitro models. Wounds. 2017 Jan;29(1):28-38. Dermacyte® is regulated by the U.S. FDA under 21 CFR Part 1271 and Section 361 of the Public Health Service Act. Dermacyte® is a registered trademark of Merakris Therapeutics Inc. Copyright © 2021 Merakris Therapeutics.
MK-0001.02
Page 1 Page 2 Page 3 Page 4Made with FlippingBook - Online magazine maker